Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hua Reports Positive Interim Results from Novel Type 2 Diabetes Candidate

publication date: Jul 2, 2020

Hua Medicine of Shanghai reported positive 24-week top-line results from a China Phase III of dorzagliatin, a global first-in-class glucokinase activator, among patients with type 2 diabetes. Dorzagliatin was administered together with metformin and compared with metformin plus placebo. An oral drug, dorzagliatin produced a sustained HbA1c reduction of 1.02% from baseline, compared to the placebo's 0.66% reduction. Hua said it is looking for one or more partners to market the drug globally. More details....

Stock Symbol: (HK: 2552)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China